Astronics (ATRO) Q3 2024 earnings summary

Executive summary

• Sales grew 25% year-over-year in Q3 2024 to $203.7 million, reaching the high end of guidance, driven by strong Aerospace and Test Systems performance.

• Adjusted net income was $12.2 million ($0.35/share), adjusted EBITDA was $27.1 million (13.3% margin), and net loss narrowed to $11.7 million ($0.34/share), impacted by $7 million in refinancing costs.

• Backlog at quarter-end was $611.9 million, with bookings of $189.2 million and a book-to-bill ratio of 0.93 for the quarter and 1.02 for the trailing twelve months.

• Strong operational performance and margin improvement initiatives led to gross margin of 21% (adjusted 23.2%) and operating margin of 4.1% (adjusted 9.6%).

• Legal and restructuring activities, including ongoing patent litigation and workforce alignment in Test Systems, significantly impacted results.

Financial highlights

• Q3 2024 sales were $203.7 million (up from $162.9 million); YTD sales reached $586.9 million.

• Gross profit was $42.7 million (21.0% margin); adjusted gross profit was $47.2 million (23.2% margin).

• Adjusted operating income was $19.6 million (9.6% margin); adjusted EBITDA margin expanded to 13.3%.

• Net debt at quarter-end was $174.6 million, with $8.5 million cash generated from operations in Q3.

• Q3 2024 loss on extinguishment of debt was $7.0 million; YTD interest expense was $17.8 million.

Outlook and guidance

• Q4 2024 sales expected between $190 million and $210 million; full-year 2024 revenue guidance raised to $777 million–$797 million, implying 14.2% growth at midpoint.

• 2025 is expected to show continued growth and margin improvement, though at a slower pace; detailed 2025 guidance to be released later.

• Planned 2024 capital expenditures are $9 million–$11 million.

• Test Systems restructuring expected to yield $2 million in annualized savings starting Q1 2025.

• Company expects cash flow from operations to fund ongoing operations; scenario planning underway for legal outcomes.